Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa [tumour necrosis factor alpha] monoclonal antibody, administered subcutaneously in subjects with active rheumatoid arthritis and previously treated with biologic anti- TNFa agent(s).

Next Previous
X
Search
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa [tumour necrosis factor alpha] monoclonal antibody, administered subcutaneously in subjects with active rheumatoid arthritis and previously treated with biologic anti- TNFa agent(s).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO-AFTER
  • Sponsors Centocor

    • Most Recent Events

    • 01 Dec 2023 Results of post hoc pooled analysis from GO-BEFORE, GO-AFTER, and GO-FORWARD, GO-REVEAL and GO-RAISE assessing Long-term golimumab persistence, published in the Clinical Rheumatology
    • 04 Jun 2022 Results assessing probability of GLM treatment retention over a 5-year period in adult patients with immune-mediated rheumatic diseases, by indication and line of therapy, using pooled data from five Phase III trials (GO-BEFORE, GO-AFTER and GO-FORWARD 3,8 ), PsA (GO-REVEAL), and AS (GO-RAISE)) presented at the 23rd Annual Congress of the European League Against Rheumatism.
    • 05 Jun 2021 Results (n=398) a post hoc analysis of GO-AFTER and the SIRROUND-T trials investigating golimumab and sirukumab, respectively, compared with PLC in patients who had an insufficient response to biological DMARDs presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top